Menu

Medical

Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®

, ,

Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Merck’s Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON, November 9, 2014–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential […]

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time

, , ,

By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J., November 6, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – the […]

Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014

,

Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company’s Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company’s oncology and […]

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV

, , ,

High Rates of Viral Suppression and Improved Renal and Bone Safety Demonstrated in Phase 3 Studies First of Several TAF-Based Single Tablet Regimens Being Evaluated by Gilead FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 6, 2014– Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug […]

Sequenta and Collaborators to Present Data on ClonoSIGHT MRD Test at American Society of Hematology Annual Meeting

,

15 presentations focus on next-generation sequencing-based MRD detection in a range of blood cancers, including diffuse large B-cell lymphoma and multiple myeloma SOUTH SAN FRANCISCO, Calif. NOVEMBER 6, 2014 – Sequenta, Inc. and its academic collaborators will present data on the ClonoSIGHT™ minimal residual disease (MRD) test in one oral and 14 poster presentations at […]

Researchers to Present Data on Improving the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2014 Annual Meeting

,

CHESHIRE, Conn. November 6, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present data from clinical studies of Soliris® (eculizumab) in patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening and ultra-rare diseases caused by chronic uncontrolled complement activation, as well as data from the Global aHUS […]

North Wales first in Europe to connect cardiology departments with GE Healthcare’s Centricity Cardio Enterprise solution

, ,

GE Healthcare supporting a number of European hospitals to improve efficiency and patient-care via innovative integrated care solutions Birmingham, 4 November 2014 – GE Healthcare is sharing information on several partnerships focusing on integrated care at EHI Live on the 4-5 November in Birmingham, UK. In North Wales, Betsi Cadwaladr University Health Board is to […]

Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer

, ,

Study Failed to Meet Secondary Endpoint of Overall Survival THOUSAND OAKS, Calif., Nov. 4, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not […]

Healthiest Employers Awards Cambia Health Solutions Second Place Among Large Oregon Employers

,

PORTLAND, OCTOBER 31, 2014 – Healthiest Employers, a data analytics company that recognizes healthy workplaces, has ranked Cambia Health Solutions second among Oregon large employers competing in the annual statewide event. “We are honored to be recognized as one of the healthiest employers in Oregon,” says Mark Stimpson, vice president of human resources. “Cambia has been […]

GE Healthcare launches startup campus Health Innovation Village to help entrepreneurs speed up health tech solutions

,

Helsinki, Finland – October 28, 2014 – Today GE Healthcare officially opens Health Innovation Village, its first health tech startup campus, at its Finnish headquarters with the Minister of Economic Affairs in Finland, Jan Vapaavuori and the Mayor of Helsinki, Jussi Pajunen. The Health Innovation Village saw its first inhabitants move in this summer. Today, […]

«‹ 25 26 27 28›»